AstraZeneca has been on roll lately, inking COVID-19 vaccine supply deals left and right with countries worldwide. One of its highest-profile pacts—a purchase deal with the European Union—was made official earlier this month, and now, the trading bloc has floated a price for its initial supply order.
The European Commission put up a €336 million ($396 million) down payment to secure its first 300 million doses of AstraZeneca and the University of Oxford’s coronavirus hopeful, AZD1222, a Commission spokesperson told Reuters Thursday.
